a relatively new type of pain-relieving drug that selectively blocks the enzyme cox-2 (cyclooxygenase-2); blocking this enzyme stops production of prostaglandins, which cause inflammation.
an anti-inflammatory drug that blocks Cox-2 activity without impeding the activity of Cox-1; "Cox-2 inhibitors reduce the symptoms of arthritis without endangering the stomach and kidneys"
A drug that selectively blocks COX-2 and leaves COX-1 alone, thereby relieving inflammation without causing stomach irritation and bleeding
A drug designed to treat chronic pain without irritating the stomach and stomach lining.
Cyclooxygenase-2 inhibitor. A class of nonsteroidal anti-inflammatory medication that works by blocking the enzyme COX-2, preventing pain and swelling associated with arthritis.
Cyclooxygenase-2 inhibitor. A nonsteroidal anti-inflammatory medication used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer medications for breast cancer.
A nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits an enzyme known as cyclooxygenase-2 (COX-2). These drugs are used to treat pain and may be less likely to cause gastrointestinal bleeding than other NSAIDs.
COX-2 selective inhibitor is a form of Non-steroidal anti-inflammatory drug (NSAID) that directly targets COX-2, an enzyme responsible for inflammation and pain. Selectivity for COX-2 reduces the risk of peptic ulceration, and is the main feature of celecoxib, rofecoxib and other members of this drug class. Cox-2-selectivity does not seem to affect other adverse-effects of NSAIDs (most notably an increased risk of renal failure), and some results have aroused the suspicion that there might be an increase in the risk for heart attack, thrombosis and stroke by a relative increase in thromboxane.